Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With B-cell Lymphoma or Leukemia

Trial Profile

Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With B-cell Lymphoma or Leukemia

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs Axicabtagene ciloleucel (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Acute lymphoblastic leukaemia; B cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoid leukaemia; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 20 Jul 2017 According to a Kite Pharma media release, results from this trial have been published in Molecular Therapy.
    • 10 Jun 2017 Biomarkers information updated
    • 14 Mar 2017 Results demonstrating durable complete remission in patients with relapsed/refractory non-Hodgkin Lymphoma published in a Kite Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top